TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00541034

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pentostatin
Study: NCT03642236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib 420mg day -3 to d14 combining with chemotherapy with/without sorafenib based on whether the patients are naive to sorafenib before relapse.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibrutinib
Description: Ibrutinib 420mg day -3 to d14 combining with chemotherapy with/without sorafenib based on whether the patients are naive to sorafenib before relapse.
Study: NCT04506489

Intervention type: OTHER
Intervention: Psychological investigation
Description: Psychological tests, psychological interviews.
Study: NCT02165293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7033877 + Bronchoscopy
Description: Days 1, 2, and 3: 2.5 mg/kg RO7033877 infused IV over 2 hours, every 8 hours for a total of 7 doses; BAL procedure on Day 3.
Study: NCT01437644

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: botulinum toxin intramuscular injection
Description: A single dose of active drug or placebo will be administered immediately prior to surgery.~The injections will be given to the anaesthetised child before the surgical procedure begins. The surgeon will perform the injections at three muscle groups around each hip: the adductors, hamstrings and iliopsoas muscles. Two units per kilogram will be given at each site. The maximum dose will be 12 units per kilogram or 500 units in total (whichever is the lesser), divided equally between six or three sites. Each active drug vial will contain 100 iu of the Botox preparation. The volume injected will be dependent on the weight of the child. Injections of normal saline will be administered in those children randomised to the placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: botulinum toxin intramuscular injection
Description: A single dose of active drug or placebo will be administered immediately prior to surgery.~The injections will be given to the anaesthetised child before the surgical procedure begins. The surgeon will perform the injections at three muscle groups around each hip: the adductors, hamstrings and iliopsoas muscles. Two units per kilogram will be given at each site. The maximum dose will be 12 units per kilogram or 500 units in total (whichever is the lesser), divided equally between six or three sites. Each active drug vial will contain 100 iu of the Botox preparation. The volume injected will be dependent on the weight of the child. Injections of normal saline will be administered in those children randomised to the placebo.
Study: NCT02144506

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: T&E

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: OTAGO
Study: NCT02435680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCS110
Description: taken by I.V

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: taken by I.V

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Description: taken by I.V

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: taken by I.V

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine
Description: taken by I.V
Study: NCT04683081

Intervention type: DEVICE
Intervention: mechanical cervical ripening
Description: mechanical cervical ripening methods have been used to make the cervix more eligible for vaginal delivery

Intervention type: DEVICE
Intervention: mechanical cervical ripening
Description: mechanical cervical ripening methods have been used to make the cervix more eligible for vaginal delivery

Intervention type: DEVICE
Intervention: mechanical cervical ripening
Description: mechanical cervical ripening methods have been used to make the cervix more eligible for vaginal delivery
Study: NCT01996267

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PTC+Pertuzumab
Description: Cycle repeated every 21 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FEC-T+Pertuzumab
Description: Cycle is repeated every 21 days
Study: NCT01945645

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ready to act
Description: The Ready to Act programme aimed to promote health-related action competence including motivation, informed decision-making, action experience and social involvement The intervention was delivered across a number of primary care settings including the GP office, health centre and pharmacy. The programme consisted of two individual counselling interviews and eight group sessions, which totalled 18 hours within a three month period.
Study: NCT01309906

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational lens
Description: Bausch \& Lomb investigational silicone hydrogel contact lens worn on a daily wear basis for 1 week.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Air Optix Aqua lens
Description: Ciba Visions Air Optix Aqua contact lens, worn on a daily wear basis for 1 week.
Study: NCT04391595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: 100 mg of Abemaciclib BID for 11 doses over 5.5 days prior to surgical resection. Participants with tumors demonstrating PK-response in Phase 0 will continue treatment with recommended Phase 2 dose (RP2D) continuously in 21d cycles after surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3214996
Description: 400 mg of LY3214996 daily for 6 doses over 5.5 days prior to surgical resection. Participants with tumors demonstrating PK-response in Phase 0 will continue treatment with recommended Phase 2 dose (RP2D) continuously in 21d cycles after surgery.
Study: NCT01688947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V116517 50-mg tablets
Description: Taken orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V116517 30-mg tablets
Description: Taken orally twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin capsules
Description: 1-2 capsules taken orally twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets to match V116517 taken orally twice daily and/or placebo capsules to match pregabalin, 1-2 capsules taken orally twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Tablets to match V116517 taken orally twice daily and/or placebo capsules to match pregabalin, 1-2 capsules taken orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablets to match V116517 taken orally twice daily and/or placebo capsules to match pregabalin, 1-2 capsules taken orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablets to match V116517 taken orally twice daily and/or placebo capsules to match pregabalin, 1-2 capsules taken orally twice daily
Study: NCT02521233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan + Chlorthalidone (8mg+12,5mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan + Chlorthalidone (8 mg + 25 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: losartan+hydrochlorothiazide
Study: NCT02337283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809
Description: Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809
Description: Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809
Description: Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809
Description: Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809
Description: Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809
Description: Tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets
Study: NCT00609180

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The study placebo will be administered through a feeding tube every 12 hours as a 120 cc bolus. Dosing will continue for 21 days or until discontinuation of mechanical ventilation.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The study placebo will be administered through a feeding tube every 12 hours as a 120 cc bolus. Dosing will continue for 21 days or until discontinuation of mechanical ventilation.
Study: NCT02448979

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Left thoracotomy
Description: Transthoracic approach is the surgical procedure including the open and minimally invasive thoracotomy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Right thoracotomy
Description: Transthoracic approach is the surgical procedure including the open and minimally invasive thoracotomy.
Study: NCT01134406

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hydros Joint Therapy
Description: Single intra-articular injection.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hydros-TA Joint Therapy
Description: Single intra-articular injection

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Synvisc-One
Description: Single intra-articular injection.
Study: NCT02912130

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein Supplementation
Description: 1.2-1.5g/kg/body weight per day
Study: NCT02583399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Ibuprofen, 10 mg/kg
Study: NCT02481440

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: human umbilical cord mesenchymal stem cells (hUC-MSCs)
Description: Four times of intrathecal administrations of hUC-MSCs
Study: NCT02857205

Intervention type: OTHER
Group type: OTHER
Intervention: Fecal samples
Description: High throughput sequencing methods and analysis for microbiome analysis on fecal samples from a multicenter cohort of patients at various ages.
Study: NCT01637792

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Three 2-liter exchanges daily CAPD
Description: CAPD regimen of three 2-liter daily exchanges

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Four 2-liter exchanges daily CAPD
Description: CAPD regimen of four 2-liter daily exchagnes
Study: NCT02912130

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein Supplementation
Description: 1.2-1.5g/kg/body weight per day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: 30-60 minutes per week of moderate intensity exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: 30-60 minutes per week of moderate intensity exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Exercise
Description: 60 minutes per week of progressive resistance training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Exercise
Description: 60 minutes per week of progressive resistance training
Study: NCT01359761

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Post Admission Cognitive Therapy (PACT)
Description: Six (60-90 minutes) individual psychotherapy sessions administered over preferably 3 days of inpatient stay, up to 2 booster sessions during hospitalization, and 4 telephone booster sessions within 3-months post discharge
Study: NCT00596245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT400
Description: MT 400, naproxen sodium 550mg
Study: NCT03708484

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Interval Training
Description: Aerobic Interval Training Patients in this group will perform 6 minutes of cycling followed by 3 minutes of pause and again 6 minutes of cycling followed by 3 minutes of pause and finally 6 minutes of treadmill followed by 3 minutes of rest.~both groups will perform cool down exercises that include again breathing exercises, stretching and active exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic + Resistive Interval Training
Description: Aerobic + Resistive Interval Training Patients in this group; first set will perform 3 minute of cycling ,1 set of hand grippers 1.5 to 2.5 lbs (10 to 12 reps) and 1 set of biceps resistive exercises 1 Kg to 3 kg (10 to 12 reps) followed by 3minute of pause. In second set patient will perform 3 minutes of stationary cycling , 1 set of quadriceps resistive exercises 1 to 3 Kg (10 to 12 reps) again followed by 3 minutes of pause and in third set patient will perform 3 minutes of treadmill walk at 1.5 to 4 speed, and 1 set of standing ankle pumps (10 to 12 reps).~both groups will perform cool down exercises that include again breathing exercises, stretching and active exercises.
Study: NCT04264182

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ICD programming
Description: Re-programming of the ICD device for VA detection (see above)
Study: NCT04334044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib Oral Tablet
Description: Ruxolitinib 5 mg twice a day
Study: NCT03076086

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Induced sputum procedure
Description: induced sputum is a sputum specimen produced for diagnostic tests by aerosol administration of a hypertonic saline solution.
Study: NCT03846531

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nano-Pulse Stimulation (NPS)
Description: The Pulse generator delivers electrical pulses (nanosecond duration) that are applied directly to targeted lesion using sterile treatment tips with micro-needles.
Study: NCT00361699

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Statin
Study: NCT00673023

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary experiments
Description: Dietary Supplement: high PUFA diet followed by high SFA diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary experiments
Description: Dietary Supplement: high PUFA diet followed by high SFA diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary experiments
Description: Dietary Supplement: high PUFA diet followed by high SFA diet
Study: NCT04326244

Intervention type: DIAGNOSTIC_TEST
Intervention: blood test
Description: High-density lipoprotein- cholesterol, Low-density lipoprotein- cholesterol, Total cholesterol, Triglyceride, Leptin, Glucose AC, Hemoglobin A1C, Insulin

Intervention type: DIAGNOSTIC_TEST
Intervention: genetic test
Description: FTO、MC4R、BDNF、PPARG、ADRB3、UCP1

Intervention type: DIAGNOSTIC_TEST
Intervention: Constitution in Chinese Medicine Questionnaire
Description: Constitution in Chinese Medicine Questionnaire

Intervention type: DIAGNOSTIC_TEST
Intervention: Epworth Sleepiness Scale
Description: Epworth Sleepiness Scale

Intervention type: DIAGNOSTIC_TEST
Intervention: cephalometry
Description: Evaluation of craniofacial morphology in OSA patients

Intervention type: DIAGNOSTIC_TEST
Intervention: polysomnography
Description: to evaluate Apnea-Hypopnea Index (AHI) for the severity of sleep apnea
Study: NCT01070563

Intervention type: OTHER
Intervention: Transcranial doppler
Description: A TCD is performed on all cerebral arteries (mean cerebral arteries, anterior cerebral arteries, basilar trunk, vertebral arteries and carotid arteries) until a flow pattern compatible with brain death is found
Study: NCT02539498

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HR-pQCT
Description: HR-pQCT to evaluate cortical and trabecular bone

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HR-pQCT
Description: HR-pQCT to evaluate cortical and trabecular bone
Study: NCT00364000

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium acetate
Description: Calcium acetate in 240 chronic HD patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium acetate
Description: Calcium acetate in 240 chronic HD patients
Study: NCT04029389

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Injection
Description: Local corticosteroid injection

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tibial nerve block
Description: Tibial nerve block
Study: NCT01757054

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ProNutrients Probiotic
Description: Dosage is 1 individually wrapped packet (1 gram) containing probiotic powder per day for 21 days
Study: NCT00553150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Study: NCT02819999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Study: NCT04029389

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conservational therapy
Description: Only exercise and foot insoles
Study: NCT01666119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEMA Buprenorphine NX films
Description: BEMA Buprenorphine NX films (3.5/0.6 mg and 5.25/0.9 mg buprenorphine/naloxone) will be provided in 3.361 and 5.447 cm2 film sizes, respectively.
Study: NCT02819999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Study: NCT02343094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBA 7,5g/d
Description: Treatment for 14 days with PBA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBA 15g/d
Description: Treatment for 14 days with PBA
Study: NCT00553150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Study: NCT00554619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1325760A
Description: 2.5mg, 5mg or 10mg/day, po, GSK1325760A treatment will be continued until its approval by the MHLW.
Study: NCT02088073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium zirconium cyclosilicate
Description: Sodium zirconium cyclosilicate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium zirconium cyclosilicate
Description: Sodium zirconium cyclosilicate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium zirconium cyclosilicate
Description: Sodium zirconium cyclosilicate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium zirconium cyclosilicate
Description: Sodium zirconium cyclosilicate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Randomized to mimic doses of experimental drug administered once daily with breakfast for 28 days (maintenance phase)
Study: NCT04253899

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Appendectomy
Description: Interval Appendectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Appendectomy
Description: Interval Appendectomy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Observation
Description: observation and follow up
Study: NCT00553150

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation
Study: NCT04229615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib; Apatinib
Description: Drug: Fluzoparib Orally twice daily; Apatinib Orally once daily
Study: NCT04253899

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Observation
Description: observation and follow up
Study: NCT04507451

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: inspiratory and expiratory muscle training
Description: inspiratory muscle training using threshold IMT device expiratory muscle training using a bottle filled of water
Study: NCT04229615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib
Description: Fluzoparib Orally twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04507451

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: inspiratory and expiratory exercises
Description: inspiratory exercise using fractionated inspirations expiratory exercise using a bottle filled with water at a minimum level
Study: NCT00665847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etravirine (TMC125)
Description: Patients will be dosed by body weight , i.e. 5.2 mg/kg twice daily (b.i.d.) up to a maximum of 200 mg b.i.d. for 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimized background regimen (OBR)
Description: An investigator-selected optimized background regimen (OBR) comprising of a low-dose ritonavir (rtv)-boosted protease inhibitor (PI) (either lopinavir \[LPV\], darunavir \[DRV\], atazanavir \[ATV\] or saquinavir \[SQV\]) in combination with nucleos(t)ide reverse transcriptase inhibitor(s) (N\[t\]RTIs) to be dosed according to the drugs individual package inserts for 48 weeks.
Study: NCT03965533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2831781
Description: GSK2831781 will be available as Dose-1 and Dose-2 as IV infusion or SC injection. Subjects will receive GSK2831781 Dose-1 IV diluted in 0.9% saline or GSK2831781 SC as multiples of Dose-2 SC.
Study: NCT00899717

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Occlusal adjustment
Description: modification of occlusal surfaces

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo occlusal adjustment
Description: Simulated modification of occlusal surfaces
Study: NCT01427517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: Single, intravenous administration of N-acetylcysteine
Study: NCT02792491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone
Description: Reduced dose of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone
Study: NCT03965533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2831781
Description: GSK2831781 will be available as Dose-1 and Dose-2 as IV infusion or SC injection. Subjects will receive GSK2831781 Dose-1 IV diluted in 0.9% saline or GSK2831781 SC as multiples of Dose-2 SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2831781
Description: GSK2831781 will be available as Dose-1 and Dose-2 as IV infusion or SC injection. Subjects will receive GSK2831781 Dose-1 IV diluted in 0.9% saline or GSK2831781 SC as multiples of Dose-2 SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2831781
Description: GSK2831781 will be available as Dose-1 and Dose-2 as IV infusion or SC injection. Subjects will receive GSK2831781 Dose-1 IV diluted in 0.9% saline or GSK2831781 SC as multiples of Dose-2 SC.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be 0.9% saline solution which will be administered in subjects as IV infusion or SC injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be 0.9% saline solution which will be administered in subjects as IV infusion or SC injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be 0.9% saline solution which will be administered in subjects as IV infusion or SC injection.